Positioned to expand access across an underserved clinical market.
The RxAir360 chamber is not FDA cleared and is not available for clinical use.
Request Access to Investor MaterialsHyperbaric oxygen therapy (HBOT) is clinically validated, FDA-cleared, and reimbursed — yet remains concentrated in fewer than 1,400 facilities across the United States.
The result is a clear gap between proven treatment and real-world access.
RxAir360 intends to address that gap by enabling physician-based access — bringing HBOT closer to the environments where patients already receive care, pending FDA 510(k) clearance.
Note: RxAir360's device is in pre-revenue stage. HBOT therapy at existing cleared facilities is FDA-approved for certain indications; the RxAir360 chamber has not received FDA clearance.
This is not a new therapy.
It is a new way of delivering it.
Healthcare has already undergone this transition in other categories:
Dialysis moved into outpatient centers
Imaging expanded into freestanding facilities
Surgery shifted into ambulatory environments
Each shift increased access and expanded the market.
Hyperbaric medicine may be positioned for the same
transition.
RxAir360 is developing a physician-integrated model designed to:
Designed to extend HBOT beyond hospital systems into physician offices
Intended to align with existing Medicare and insurance frameworks
Designed to fit into everyday clinical workflows seamlessly
The focus is not just technology — but enabling access at scale, pending FDA 510(k) clearance.
RxAir360's device is not FDA cleared and cannot be sold or marketed for clinical use until regulatory approval is obtained.
Regulatory Notice: Basis of Accounting: Accrual Basis — U.S. GAAP | Report Type: Unaudited — Management Prepared | Regulatory Purpose: OTC Markets / FINRA Form 211 Submission | Date Prepared: April 10, 2026
RxAir360 intends to pursue quotation on the OTC Markets and has submitted Form 211 to FINRA. The review process is ongoing.
This is not an offer to sell or solicitation of securities.
Access detailed materials, financials, and supporting documentation designed to provide a clear view of the RxAir360 platform, market opportunity, and development progress.
RxAir360 is positioned to expand access to hyperbaric oxygen therapy within an underserved outpatient market.
This is not an offer to sell or solicitation of securities. Available to accredited investors only.
Available to qualified and accredited investors.
Request Access to Investor MaterialsCommunity Initiative: Through RxAir Cares, a registered 501(c)(3) nonprofit, RxAir360 is actively supporting initiatives focused on expanding access to hyperbaric oxygen therapy in underserved populations.
Investment in RxAir360 involves substantial risks, including the risk of total loss of investment. This is not investment advice.
Forward-Looking Statements
This website contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from any future results expressed or implied by these statements. Forward-looking statements include, but are not limited to, statements regarding product development timelines, regulatory submissions, market opportunity, and commercialization plans.
Investment Risks
No Offer or Solicitation
This website does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offering or sale of securities will be made only pursuant to formal offering documents in compliance with applicable federal and state securities laws. Securities offered herein have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold absent such registration or an applicable exemption.
Full risk disclosures are available upon request. This is not investment advice. Consult a qualified financial advisor before making any investment decisions.